CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: November 20, 2015
Result type: Reports
Project Number: SR0461-000
Product Line: Reimbursement Review

Generic Name: Mepolizumab

Brand Name: Nucala

Manufacturer: GlaxoSmithKline Inc.

Therapeutic Area: Asthma, severe eosinophilic

Indications: Asthma, severe eosinophilic

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: June 16, 2016

Recommendation Type: Reimburse with clinical criteria and/or conditions